| Dr Thomas David Gall, OD | |
|
2209 N 5th St, Elko, NV 89801-2458 | |
| (775) 738-8491 | |
| (775) 738-3313 |
| Full Name | Dr Thomas David Gall |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 6 Years |
| Location | 2209 N 5th St, Elko, Nevada |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083109151 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | OPT-002270 (Arizona) | Secondary |
| 152W00000X | Optometrist | 1004 (Nevada) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Colon And Alleman Ltd | 4880671320 | 5 |
News Archive
An international team of researchers, led by scientists at the National University of Singapore (NUS), has identified a protein that regulates the growth of neurons by transporting key metabolic enzymes to the tips of neural cells.
BHR Pharma, LLC (BHR) announced today that it will initiate a global, Phase 3, multi-center pivotal trial (www.synapse-trial.com) to evaluate the effectiveness of its proprietary BHR-100 intravenous progesterone infusion product as a neuroprotective agent for treating severe traumatic brain injury (TBI) patients in early 2010.
Scientists are reporting a possible explanation for the bone loss that may occur following long-term use of a medicine widely used to treat epilepsy, bipolar disorder, and other conditions. The drug, valproate, appears to reduce the formation of two key proteins important for bone strength, they said. Their study, which offers a solution to a long-standing mystery, appears in ACS' monthly Journal of Proteome Research.
Larry Ambrose woke up one night, wandered into his kitchen but couldn't completely read the time on his microwave. A few days later when he noticed his blood pressure was unusually high, he went to the hospital and was diagnosed as having a stroke.
The first test in a mammalian model of a potential new class of drugs to treat Parkinson's disease shows abatement of neurodegeneration in the brains of test rats and no significant toxicities, University of Alabama at Birmingham and Pfizer Inc. researchers report online in The Journal of Biological Chemistry.
› Verified 7 days ago
| Provider Name | Colon & Alleman Ltd |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1760568422 PECOS PAC ID: 4880671320 Enrollment ID: O20040702000290 |
News Archive
An international team of researchers, led by scientists at the National University of Singapore (NUS), has identified a protein that regulates the growth of neurons by transporting key metabolic enzymes to the tips of neural cells.
BHR Pharma, LLC (BHR) announced today that it will initiate a global, Phase 3, multi-center pivotal trial (www.synapse-trial.com) to evaluate the effectiveness of its proprietary BHR-100 intravenous progesterone infusion product as a neuroprotective agent for treating severe traumatic brain injury (TBI) patients in early 2010.
Scientists are reporting a possible explanation for the bone loss that may occur following long-term use of a medicine widely used to treat epilepsy, bipolar disorder, and other conditions. The drug, valproate, appears to reduce the formation of two key proteins important for bone strength, they said. Their study, which offers a solution to a long-standing mystery, appears in ACS' monthly Journal of Proteome Research.
Larry Ambrose woke up one night, wandered into his kitchen but couldn't completely read the time on his microwave. A few days later when he noticed his blood pressure was unusually high, he went to the hospital and was diagnosed as having a stroke.
The first test in a mammalian model of a potential new class of drugs to treat Parkinson's disease shows abatement of neurodegeneration in the brains of test rats and no significant toxicities, University of Alabama at Birmingham and Pfizer Inc. researchers report online in The Journal of Biological Chemistry.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Thomas David Gall, OD 1050 Hanson St, Winnemucca, NV 89445-2774 Ph: (775) 625-3937 | Dr Thomas David Gall, OD 2209 N 5th St, Elko, NV 89801-2458 Ph: (775) 738-8491 |
News Archive
An international team of researchers, led by scientists at the National University of Singapore (NUS), has identified a protein that regulates the growth of neurons by transporting key metabolic enzymes to the tips of neural cells.
BHR Pharma, LLC (BHR) announced today that it will initiate a global, Phase 3, multi-center pivotal trial (www.synapse-trial.com) to evaluate the effectiveness of its proprietary BHR-100 intravenous progesterone infusion product as a neuroprotective agent for treating severe traumatic brain injury (TBI) patients in early 2010.
Scientists are reporting a possible explanation for the bone loss that may occur following long-term use of a medicine widely used to treat epilepsy, bipolar disorder, and other conditions. The drug, valproate, appears to reduce the formation of two key proteins important for bone strength, they said. Their study, which offers a solution to a long-standing mystery, appears in ACS' monthly Journal of Proteome Research.
Larry Ambrose woke up one night, wandered into his kitchen but couldn't completely read the time on his microwave. A few days later when he noticed his blood pressure was unusually high, he went to the hospital and was diagnosed as having a stroke.
The first test in a mammalian model of a potential new class of drugs to treat Parkinson's disease shows abatement of neurodegeneration in the brains of test rats and no significant toxicities, University of Alabama at Birmingham and Pfizer Inc. researchers report online in The Journal of Biological Chemistry.
› Verified 7 days ago
Vision Consultants Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2850 Ruby Vista Dr, Elko, NV 89801 Phone: 775-375-8869 | |
Dr. Micah Williams, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2209 N 5th St, Elko, NV 89801 Phone: 775-738-8491 Fax: 775-738-3313 | |
Dr. Spencer James Mcconkie, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2209 N 5th St, Elko, NV 89801 Phone: 775-738-8491 Fax: 775-738-3313 | |
Dr. Shaune Wallace, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1657 Mountain City Hwy Ste 101, Elko, NV 89801 Phone: 775-738-6727 | |
Steven Day, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2944 Mountain City Hwy, Elko, NV 89801 Phone: 775-777-0976 Fax: 775-738-8062 | |
Dr. Kurt G Alleman, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 2209 N 5th St, Elko, NV 89801 Phone: 775-738-8491 Fax: 775-738-3313 |